论文部分内容阅读
目的:甲泼尼龙冲击疗法(MPPT)治疗重症肌无力(MG)57例的近期疗效及1～3年随访观察。方法:MPPT和泼尼松治疗57例重症肌无力患者,按美国重症肌无力协会临床分型为Ⅰ型25例,Ⅱa型13例,Ⅱb型7例,Ⅲa型5例,Ⅲb型3例,Ⅳb型1例,Ⅴ型3例,均予以甲泼尼龙,成人1000mg·d-1,儿童20～30mg/(kg·d)溶于5%葡萄糖液内缓慢静脉滴注,3d为1疗程,每月1疗程,共3疗程。结果:近期疗效(半个月内)为:完全缓解21例(36.8%),部分缓解29例(50.8%),未改善7例(12.3%);随访1、2和3年时的完全缓解率分别为81.1%、88.4%、93.2%。结论:MPPT治疗MG1～3年缓解率较高。
Objective: To observe the short-term curative effect and follow-up of 1 to 3 years in 57 cases of myasthenia gravis (MG) treated by methylprednisolone impact therapy (MPPT). Methods: Fifty-seven patients with myasthenia gravis were treated with MPPT and prednisone. According to the American Society of Myasthenia Gravis Association, 25 cases were type Ⅰ, 13 cases were type Ⅱa, 7 cases were type Ⅱb, 5 cases were type Ⅲa and 3 cases were type Ⅲb. 1 case of Ⅳb type and 3 cases of type Ⅴ were treated with methylprednisolone, adult 1000mg · d-1 and children 20 ~ 30mg / (kg · d) in 5% dextrose solution by slow intravenous drip. 3d was a course of treatment, 1 course of treatment per month, a total of 3 courses. Results: The short-term efficacy (within half a month) was complete remission in 21 cases (36.8%), partial remission in 29 cases (50.8%) and no improvement in 7 cases (12.3%); Rates were 81.1%, 88.4%, 93.2% respectively. Conclusion: MPPT treatment of MG 1 ~ 3 years higher remission rate.